drugset / Trial / NCT07654179

Metformin as Adjunct Therapy in Depression-Obesity Comorbidity: Clinical and Genetic Evaluation

NCT07654179

Recruiting 200 enrolled Riphah International University
RandomizedParallel-groupOpen-labelTreatment

Summary

The patients with depression and obesity will receive add-on metformin with antidepressant therapy, which may result in greater improvement in depressive symptoms and BMI reduction compared to antidepressant monotherapy. NEGR1/RPL31P12 gene polymorphisms may influence the comparative efficacy of antidepressant monotherapy versus combination therapy (antidepressant + metformin) in Pakistani patients. Patients with certain variants may respond better or worse to antidepressants and may have different weight outcomes.

Timeline

Start
2026-06-17
Primary completion
2027-06-11
Completion
2027-06-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Bupropion Small molecule 150 mg
Subject Bupropion Small molecule 300 mg
Subject Duloxetine Small molecule 60 mg
Subject Metformin Small molecule 500 mg
Subject Metformin Small molecule 1000 mg
Subject Sertraline Small molecule 50 mg